Business Today – 19 July 2026
Summary
Anil Agarwal split Vedanta into five listed entities and announced a 20-billion-dollar India investment plan — Business Today's July 19, 2026 issue (Vol 35 No 15) examines whether the group can execute its most ambitious bet yet. The cover story "The New Vedanta" tracks the restructuring that created Vedanta Ltd, Hindustan Zinc, Vedanta Aluminium, Vedanta Oil & Gas, and Vedanta Power as separate listed companies. Wockhardt won US FDA approval for Zaynich, India's first wholly indigenous new drug, and the BT-C Fore Business Confidence Index dropped to 44.6 — below the 50-point threshold that signals optimism.
The Vedanta cover story details the group's debt allocation across the five entities, with Vedanta Ltd carrying 45 percent of the total 9-billion-dollar debt. The Wockhardt feature reports that Zaynich targets drug-resistant bacterial infections and was developed entirely at the company's Aurangabad R&D centre. The Business Confidence Survey of 600 companies shows that the index fell below 50 for the first time in 5 quarters, driven by margin pressure and regulatory uncertainty.
Regular sections include The Point, BT Interview, Economy, Corporate, Tech, and Real Estate.
—————
Content Guide
▸ Cover Story / Corporate Restructuring
p.20 · The New Vedanta
Vedanta's restructuring split 9 billion dollars in debt across 5 entities, with Vedanta Ltd holding the largest share at 4.05 billion. The article projects that the demerger will unlock 3-4 billion dollars in enterprise value through separate listing premiums, based on Hindustan Zinc's 40 percent valuation gain post its earlier demerger. Investment bankers can use the projected value-unlock formula to model similar conglomerate splits.
▸ Corporate / Pharma
p.36 · Patience Pays for Wockhardt
Zaynich received US FDA approval after 14 years of R&D, making it the first Indian-invented drug approved by the FDA for a new chemical entity. Wockhardt spent 850 crore rupees on development, and the global market for the antibiotic class it belongs to is valued at 3.2 billion dollars annually. Pharma analysts can benchmark Wockhardt's R&D spend-to-approval cycle against global industry averages.
▸ Economy / Business Confidence
p.30 · Red Alert!
The BT-C Fore Business Confidence Index fell to 44.6 in Q2 2026, below the 50-mark threshold for the first time since Q1 2025. Manufacturing sentiment dropped most sharply, falling 12 points, while services held relatively steady at 48.2. CFOs can use the sector-level index breakdown as a benchmark for their own sentiment surveys.
▸ Technology / Science
p.44 · India's Quantum Moonshot
India's National Quantum Mission has allocated 6,000 crore rupees for building a 100-qubit quantum computer by 2028. The article profiles 3 Indian start-ups — QNu Labs, BosonQ Psi, and QpiAI — that have already delivered commercial quantum-security products. CTOs exploring post-quantum cryptography should track the mission's timeline for standard-setting.
▸ Real Estate / Investment
p.66 · The REIT Choice
India's REIT market has grown to 70,000 crore rupees in assets under management, with Embassy Office Parks, Mindspace Business Parks, and Brookfield India leading. The article reports that average REIT dividend yields dropped to 4.8 percent from 6.2 percent a year ago as unit prices appreciated. Income-focused investors should evaluate the yield compression against fixed-income alternatives.
▸ Markets
p.8 · The Great Indian IPOs
The Point column reports that 62 companies raised 1.2 lakh crore rupees through IPOs in H1 2026, making it the busiest first half in Indian market history. The average listing-day gain dropped to 8 percent from 22 percent in 2025, signalling a cooling primary market. Equity capital market teams can use the 8 percent average listing gain in pricing discussions with issuer clients.
—————
Editor's Take
The Vedanta restructuring cover story is a textbook piece of corporate journalism — it explains a complex demerger with clear debt-allocation data and credible value-unlock projections. The Wockhardt FDA story is genuinely important for the Indian pharma narrative and deserves the prominence it gets. The Business Confidence Index drop below 50 is the kind of proprietary data point that BT does well. The tech section's quantum computing piece is a welcome addition, though it reads as a sector primer rather than a news report. The weakest link is the Real Estate page, which is too short to add real depth to the REIT discussion. The advertising density is moderate.
Strengths
• Vedanta debt allocation data is M&A-deck ready
• Wockhardt's Zaynich story is a landmark in Indian pharma
• Business Confidence Index provides proprietary economic intelligence
Weaknesses
• REIT section too brief to be useful
• Quantum piece reads as a primer, not a news feature
Verdict: Essential — The Vedanta and Wockhardt stories alone make this a must-read for corporate India watchers; the Business Confidence Index adds macroeconomic context.
